Glossary

Creatinine Clearance (CrCl)

Creatinine clearance (CrCl) is an estimate of kidney function, usually calculated with the Cockcroft-Gault formula from a patient's age, weight, sex and serum creatinine. The MHRA advises using it, not eGFR, to adjust the dose of direct-acting oral anticoagulants (DOACs).

Clinically reviewed by Aisha Malik, Clinical Director (GPhC 2205843), on .

What it means in practice

Practices see two estimates of kidney function: eGFR, which the lab reports, and creatinine clearance, which has to be calculated. The MHRA's Drug Safety Update (October 2019) says eGFR is appropriate for most patients and most medicines, but creatinine clearance should always be used to guide dose adjustment for DOACs (apixaban, dabigatran, edoxaban and rivaroxaban), because using eGFR overestimates kidney function and increases the risk of bleeding. It also applies to medicines that are largely excreted by the kidneys and have a narrow therapeutic index, such as digoxin and sotalol. SPS monitoring guidance for DOACs advises using actual body weight from the last 12 months in the calculation, and considering adjusted body weight in people over 120 kg or with a BMI over 40, unless local guidance says otherwise. DOAC dose checks are a common CQC medicines search and a frequent job for practice pharmacists.

Good practice

  • Calculate creatinine clearance with Cockcroft-Gault for every patient on a DOAC, not just read the eGFR
  • Use a recent, recorded body weight in the calculation
  • Repeat the check when kidney function changes, and at least at each DOAC review
  • Check the dose against the product's licensed thresholds for creatinine clearance
  • Record the creatinine clearance used for the dosing decision

Questions

Why not use eGFR to dose DOACs?

The MHRA says using eGFR to dose DOACs is known to increase the risk of bleeding, because it overestimates kidney function. Creatinine clearance calculated with Cockcroft-Gault should be used instead.

Which other medicines need creatinine clearance?

The MHRA names medicines that are largely excreted by the kidneys and have a narrow therapeutic index, such as digoxin and sotalol.

Which weight should I use?

SPS advises actual body weight recorded in the last 12 months for DOACs in atrial fibrillation, and considering adjusted body weight above 120 kg or a BMI over 40, unless local guidance or the anticoagulation clinic advises otherwise.

Sources

Checked against these sources on 19 November 2026.

  1. Prescribing medicines in renal impairment: using the appropriate estimate of renal function (MHRA Drug Safety Update, October 2019)
  2. DOACs (direct oral anticoagulants): monitoring (SPS)

Remote clinical pharmacists, funded through ARRS.

Book a 30-minute call